Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE CODEL
NCT05331521Phase 3Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Apr 2021
- Primary completion
- Mar 2033
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lomustine and temozolomide in Oligodendroglioma (OG) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoints: Qualified Overall Survival at 120 months, Short-term qOS deterioration in NeuroCogFX at 120 months and 4 more. Started Apr 2021; status: recruiting.
02
Drugs
lomustinetemozolomide
03
Conditions
Oligodendroglioma (OG)
Beyond the preview
Go deeper on NCT05331521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05331521.